<DOC>
	<DOCNO>NCT02913443</DOCNO>
	<brief_summary>This Phase I , open-label , multicenter study design ass safety tolerability RO7051790 participant relapse ED SCLC . This dose escalation expansion study plan determine maximum tolerate dose and/or optimal biological dose recommend Phase 2 dose RO7051790 , base safety , tolerability , pharmacokinetic pharmacodynamic profile observe oral administration RO7051790 .</brief_summary>
	<brief_title>A Dose Finding Expansion Study RO7051790 Administered Orally Participants With Relapsed , Extensive-Stage Disease Small Cell Lung Cancer ( ED SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Life expectancy great equal ( &gt; = ) 12 week Participants must histologically cytologically confirm diagnosis SCLC Participants must recurrent refractory disease receive least one prior platinumcontaining chemotherapy regimen , standard therapy refuse suitable Acute toxicity prior treatment , surgery , radiotherapy must National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 Grade less equal ( &lt; = ) 1 Measureable disease per RECIST criterion version 1.1 prior administration study medication Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow function Adequate renal function Participant must able swallow retain orally administer study treatment Women childbearing potential men agree use effective form contraception continue use duration study treatment period time last dose study treatment Active malignancy SCLC within previous 5 year Participants receive radiotherapy less 2 week prior first dose study medication Surgical procedure clinically significant trauma within 2 week first dose study treatment Treatment investigational agent &lt; =3 week prior first dose study treatment Participants gastrectomy preexist gastrointestinal disorder may interfere proper absorption drug ( ) , per conclusion clinical Investigator Participants medicate antidepressant report lysinespecific histone demethylase 1A ( KDM1A ) /lysine ( K ) specific demethylase 1A ( LSD1 ) inhibitory activity ( tranylcypromine phenelzine ) within 28 day treatment start History allergic reaction attribute component formulate product ( ) History seizure disorder History central nervous system metastases Participants severe and/or uncontrolled medical condition condition could affect participation study Participants evidence electrolyte imbalance Participants pregnant breastfeeding Participants refuse potentially receive blood product and/or hypersensitivity blood product Participants know bone marrow disorder may interfere bone marrow recovery participant delay recovery prior chemoradiotherapy Participants know coagulopathy , platelet disorder history nondruginduced thrombocytopenia Hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) positive participant active infection Use strong Cytochrome P450 3A4 ( CYP3A4 ) inducer study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>